Qiagen N.V. Qiagen N.V.

Qiagen N.V.

QGEN

Rankning i aktier #2010
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Aktiekurs
$50.10
Marknadsvärde
$10.32B
Förändring (1 dag)
2.56%
Förändring (1 år)
3.18%
Land
NL
Handel Qiagen N.V. (QGEN)

Kategori

Healthcare
Intäkter för Qiagen N.V. (QGEN)
Intäkter i Jun 2026 TTM: $2.10B
Enligt Qiagen N.V. senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $2.10B. År 2024 hade företaget intäkter på $1.98B en ökning jämfört med intäkterna år 2023, som var $1.97B. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäkts­historik för Qiagen N.V. från 2000 till 2026
Intäkter vid slutet av varje år
År Intäkter Ändra
2026 (TTM) $2.10B 0.50%
2025 $2.09B 5.65%
2024 $1.98B 0.66%
2023 $1.97B -8.23%
2022 $2.14B -4.89%
2021 $2.25B 20.39%
2020 $1.87B 22.53%
2019 $1.53B 1.64%
2018 $1.50B 5.95%
2017 $1.42B 5.95%
2016 $1.34B 4.45%
2015 $1.28B -4.74%
2014 $1.34B 3.29%
2013 $1.30B 3.79%
2012 $1.25B 7.24%
2011 $1.17B 7.57%
2010 $1.09B 7.69%
2009 $1.01B 13.09%
2008 $892.98M 37.43%
2007 $649.77M 39.50%
2006 $465.78M 16.91%
2005 $398.40M 4.67%
2004 $380.63M 8.32%
2003 $351.40M 17.68%
2002 $298.61M 13.21%
2001 $263.77M 29.28%
2000 $204.03M 0.00%
Intäkter för liknande företag eller konkurrenter
Företag Intäkter Intäktsdifferens Land
$46.34B 2,106.09%
US
$25.11B 1,095.36%
US
$2.71B 28.89%
US
- -
CN
$7.37B 250.99%
US